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Department of Urology, University Hospital Nijmegen, The Netherlands
Summary. Laser treatment of benign prostatic hyperpla­
sia has enjoyed growing popularity among urologists over 
the last few years. Various applicators and techniques have 
been reported. Because this may result in a different over­
all performance, we performed a prospective randomized 
study comparing the results of treatment using the Ultra­
line fiber (n -  44) with that using the Urolase fiber (n = 
49)* Although different types of fibers and techniques 
were used, the results of this study were surprisingly sim­
ilar for both fibers used. The uroflow for the Ultraline 
group increased from an average of 7.9 ml/s at baseline to
19.3 ml/s at 3 months and 16.9 ml/s at 6 months. In the 
patients treated with the Urolase fiber the uroflow im­
proved from an average of 7.8 ml/s at baseline to 19.5 and
16.3 ml/s at 3 and 6 months, respectively. The improve­
ment in symptoms, reflected by changes in the I-PSS 
symptom scores, for the Ultraline group went from 21,0 at 
baseline to 7.9 at 3 months and 6.0 at 6 months. The Uro­
lase patients improved from 21.0 at baseline to 8.2 and 5.6 
at 3 and 6 month, respectively. The morbidity mainly con­
sisted of a prolonged need for posttreatment catheteriza­
tion and irritative symptoms lasting for about 2 -4  weeks. 
From this study we conclude that the results achieved by 
laser treatment of the prostate using the Ultraline and Uro­
lase fibers are both equivocal and excellent; however, the 
morbidity of these treatments remains considerable.
Over the last few decades, transurethral resection of the 
prostate (TURP) has been the primary choice of treatment 
to relieve bladder-outlet obstruction and symptoms of 
prostatism. TURP is reported to be a safe and effective 
procedure, The mortality has been reduced to 0.2%, but 
the morbidity remains considerable and constant at 18% 
[1]. The treatment of BPH is currently undergoing signif­
icant réévaluation. The increasing age of the general pop- 
ulation and the greater attention paid by older men to the 
symptoms of prostatism mean that the demand for treat­
ment is almost limitless.
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Because of the minor but significant morbidity and the 
changes in social habits and for economic reasons, a num­
ber of alternatives to TURP have emerged in recent years 
[2-5]. One alternative to TURP that has recently demon­
strated significant results is the use of a laser to achieve 
deobstruction [6-8]. One of the first reports on laser treat­
ment of BPH was published by Costello et al. in 1992 [9]. 
Since then, various authors have reported their clinical ex­
perience in using different types of applicators [7, 8, 10, 
11]. These applicators, however, differ in their physical 
properties, overall performance, and tissue effects.
The question as to the type of applicator that should be 
used is fundamental. The initial experience with laser 
treatment of benign prostatic hyperplasia (BPH) involved 
the transurethral ultrasound-guided laser-induced prosta­
tectomy (TULIP) device and the Urolase fiber [12]. The 
simplicity of the endoscopy-assisted technique made it 
more attractive than the ultrasound-guided TULIP device. 
Moreover, the latter procedure caused more morbidity. 
Following this experience, we proceeded with the side-fir­
ing fiber technique. These fibers possess vaporizing and 
coagulation properties. In favor of the vaporizing tech­
nique is the observation that tissue is vaporized and a lu­
men is created instantly. On the other hand, a coagulative 
technique may result in more extensive tissue destruction 
and, thus, should lead to better results. To date, long-term 
data have not been available to demonstrate this correla­
tion with clinical results in humans. Therefore, we con­
ducted a study involving a fiber that is primarily used to 
achieve coagulation (Urolase) and a fiber that can achieve 
both vaporization and coagulation (Ultraline).
Patients and methods
From April 1993 until July 1994, 94 men aged 50-85 years (aver­
age, 65 years) with symptoms of BPH were randomized to receive 
treatment with the Ultraline fiber (Heraeus) or the Urolase fiber 
(Bard). The major inclusion and exclusion criteria for treatment 
are shown in Table 1.
Screening included a general history and complete physical ex­
amination (including a digital rectal examination), routine blood 
studies, urine microscopy, and culture. Urinary cytology and pros­
tate-specific antigen (PSA) levels were always measured so as to 
exclude coexisting malignancy, The severity of symptoms was
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Table 1. Inclusion and exclusion criteria for laser treatment
Inclusion criteria Exclusion criteria
Table 2. Baseline characteristics of the patients evaluated in the 
present study
Prostate volume, > 30 cm3 Prostatic carcinoma
Aee, > 50 years
W-
Bacterial prostatitis
Duration of symptoms, Urethral stricture
> 3 months
IPSS symptom score, > 12 Neurogenic bladder dysfunction
Peak uroflow, < 15 ml/s Urinary tract infection
Use of drugs influencing
bladder function
History of TURP or TULIP
Diabetes mellitus
Bladder residual urine, > 350 ml
scored using the IPSS questionnaire. Men were also questioned re­
garding their sexual function (erection and ejaculation). Uroflow- 
metry (peak flow, Qmax) was performed twice with a minimal 
voided volume of 100 ml. Residual urine was measured with trans­
abdominal ultrasound. To determine the grade of outlet obstruction 
we performed an advanced urodynamics investigation, including 
pressure-flow analysis. The upper urinary tract was evaluated us­
ing a plain abdominal X-ray and renal ultrasound. Transrectal ul­
trasound of the prostate (TRUS) was performed to measure the 
volume of the prostate and to determine the prostate configuration. 
Flexible urethrocystoscopy was used to verify the patency of the 
urethra and to look for an enlargement of the middle lobe and for 
signs of malignancy. All patients with an abnormal rectal exami­
nation, a PSA level of more than 10 ng/ml (Hybritech), and/or an 
abnormal TRUS underwent biopsy.
Patients were randomized after informed consent had been ob­
tained. The Urolase-fiber delivery system consists of a 4-m-long 
Teflon-coated fiber with a gold-plated dish at the tip, which allows 
the laser beam to be reflected at a 90° angle. Sterile water is used 
as an irrigant through a standard 23-F cystoscope with a 30°-angIe 
lens. The Urolase fiber is passed through the working port of the 
cystoscope. The distribution of the laser energy is customized to 
the appearance of each prostate. In general, 40 W of energy is ap­
plied for 90 s to each lateral lobe at the 2, 5, 7, and 10 o ’clock po­
sitions. In the case of an enlarged middle lobe or a prostatic urethra 
exceeding 2.5 cm in length, further applications are provided to en­
sure complete blanching of the lateral lobes. The Ultraline fiber 
system also consists of a Teflon-coated fiber and the beam is re­
flected using a refractive mechanism. The distribution of the laser 
energy is applied by a dragging or so-called painting technique 
with the fiber in the contact or noncontact mode. A total of 60 W 
of energy is delivered to the prostate lobes during a certain period. 
To provide relief of symptoms, this technique relies not on tissue 
slough but rather on the immediate creation of an open channel.
Patients were seen at 1 ,6 , 12, 26, and 52 weeks after treatment. 
When the postvoid residual urinary volume was below 100 ml and 
the micturition was restored satisfactorily, the indwelling catheter 
was removed.
Statistical analysis within each group was done with 
Wilcoxon’s signed-rank test (alpha = 0.05), whereas Student’s r- 
test (alpha = 0.005) was used for comparison between the groups.
Results
The average age of the Ultraline group was 65.0 (range, 
50-85) years, and that for the Urolase group was 64.6 
(range, 52-79) years. The average prostate volume as 
measured with TRUS was 45.7 cm3 for the ultraline group
Urolase, n — 49 
Mean (SD)
Ultraline, n 
Mean (SD)
= 44
Age (years) 64.6 (7.2) 65.0 (6.7)
IPSS symptom score 21.0 (5.1) 21.0 (5.9)
Prostatic volume (cm3) 49.7(17.2) 45.7 (14.9)
Qmax (ml/s) 7.8 (3.0) 7.9 (2.9)
Voided volume (ml) 200 (95) 196 (89)
Residual urine (ml) 86 (76) 86 (79)
PSA (ng/ml) 5.3 (4.4) 4.9 (3.9)
Table 3. Main follow-up indices after Urolase or Ultraline treat-
ment
Weeks posttreatment
0 12 26 52
Ultraline (n) 44 42 32 7
Qmax (mean, ml/s) 7.9 19.3 16.9 19.7
IPSS (mean) 21.0 7.9 6.0 6.6
PVR (mean, ml) 86 25 11 32
Urolase (n) 49 47 28 3
Qmax (mean, ml/s) 7.8 19.5 16.3 12.7
IPSS (mean) 21.0 8.2 5.6 1.7
PVR (mean, ml) 86 25 12 50
PVR, Postvoid residual urinary volume
and 49.7 cm3 for the Urolase group. There was no statis­
tical difference between the two groups for any given pa­
rameter at baseline (Table 2). In all, 89 patients were 
available at 12 weeks for assessment and 60 were evalu­
able at 26 weeks. No patient was lost to follow-up, one 
patient was treated by TURP, and one patient needed a 
bladder-neck incision because of a bladder-neck sclerosis.
Table 3 shows the subjective and objective changes 
noted after treatment. For the Ultraline group a significant 
reduction in IPSS symptom score was shown from an av­
erage of 21.0 to 7.9 after 12 weeks, to 6.0 after 26 weeks, 
and to 6.6 after 52 weeks. In the Urolase group the reduc­
tion in symptoms was similar to that seen in the Ultraline 
group, with changes occurring from 21.0 at the onset to 8.2 
after 12 weeks, to 5.6 after 26 weeks, and to 1.7 after 52 
weeks (Fig. 1). Statistical evaluation revealed a statistically 
significant reduction in symptom-score parameters for all 
values. In the Ultraline group the average improvement 
was 11.9 ml/s after 3 months and 9.6 ml/s after 6 months. 
In the Urolase group the average improvement in uroflow 
was 11.7 ml/s at 3 months and 8.6 ml/s at 6 months (Fig. 
2). A comparison between the Urolase and Ultraline groups 
after 12 and 26 weeks of follow-up showed no statistically 
significant difference with regard to symptom score (P < 
0.0001) or peak flow (P < 0.0001). The same result was 
found for the postvoid residual urinary volume (Fig. 3).
The TRUS images obtained after treatment showed 
cavities at 26 weeks in both the Ultraline and the Urolase
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Fig. 1. Improvement in sym ptom  scores (IPSS) noted for the 
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Fig* 2. Improvement in maximal uroflow (Qmax) noted for the 
a Urolase and b Ultraline groups
groups (Fig.4). No relation was found between the pros­
tate volume and the subjective and objective results ob­
tained. As shown in Table 2, PSA serum concentrations 
were normal before treatment. When they were measured 
at i day after treatment, there was an elevation in the av­
erage PSA value from 5.1 (range, < 1.0-17) ng/ml to a 
mean value of 91 (range, 3.2-290) ng/ml. After 3 months, 
the PSA level returned to normal (Fig. 5).
No complication occurred during the operation. The 
predominant complications encountered in both groups 
posttherapy were prolonged catheterization, urinary tract 
infections, and (irritative) miction complaints. No inconti­
nence occurred. Patients in the Ultraline group needed an 
indwelling catheter for an average of 18.9 days, and those 
in the Urolase group did so for 16.9 days (Fig. 6). A retro­
grade ejaculation was mentioned by 50% of the sexually 
active patients, whereas 14% of the patients complained 
of diminished or absent erectile functions.
D i s c u s s i o n
Laser light is a unique form of energy with characteristic 
and variable tissue effects. The NdrYAG laser produces a
tissue effect by converting light energy into thermal en­
ergy. Prostatic tissue heated to between 60° and 100°C 
will undergo protein denaturation and coagulation necro­
sis. Coagulation results in delayed sloughing of the pros­
tate for a variable period, usually for several weeks after 
the procedure. At temperatures above 100° C, tissue con­
verts into vapors of water and hydrocarbons, thus creating 
immediate cavitation. In general, laser energy applied to 
the prostate is aimed at deobstruction, resulting in im­
provement in objective and subjective parameters.
The ultimate acceptance of this laser technology relies 
not only on an improvement in treatment-related morbid­
ity but also on results comparable with those of TURP 
The most common method of performing laser ablation of 
BPH has been the noncontact coagulation technique, 
which uses low power in the noncontact mode to achieve 
maximal coagulation and minimal evaporation of tissue. 
Overall laser treatment using the Urolase fiber results in 
an average improvement in uroflow of 50%-100% and in 
a significant decrease in symptoms [7, 9, 12-14].
As a result of this early experience, laser prostatec­
tomy has become popular with many urologists because it 
is associated with morbidity lower than that resulting 
from TURP. Moreover, the public has become more aware
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Fig. 3. Improvement in postvoid residual urinary volume (PVR) 
noted for the a Urolase and b Ultraline groups
of other treatment options for BPH, and many men are 
hesitant to consider the traditional option of TURP. Men 
are particularly concerned regarding the risks of bleeding, 
impotence, and a prolonged postoperative recovery pe­
riod, Laser treatment meets most of these requirements.
Thus far, the results obtained after laser treatment have
1
been excellent and have approximated those achieved af­
ter TURP. The present study shows an increase in uroflow 
from 7.8 to 19.5 ml/s at 3 months for the Urolase group 
and an increase from 7.9 to 19.3 ml/s at 3 months for the 
Ultraline group. The subjective improvement measured 
with the IPSS questionnaire also showed remarkable re­
sults. In Fig. 7 the relation between symptom scores and 
maximal uroflow at baseline and at 3 and 6 months of fol­
low-up is presented.
From this figure it seems obvious that an improvement 
in uroflow is reflected in a simultaneous improvement in 
symptoms. However, a significant difference between 
laser prostatectomy and standard T U R P is the lack of im­
mediate effect for the former. A standard transurethral 
prostatectomy removes tissue at the time of  the procedure, 
and patients often experience a significant improvement 
in urinary stream as soon as the indwelling catheter is re­
moved. Although the objective and subjective results
Fig. 4, TRUS image obtained after laser treatment in the a sagittal 
and b transverse planes. A nice cavity can be appreciated
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achieved in the present study by laser therapy using the 
Urolase or Ultraline fiber were good, considerable m or­
bidity was noted.
There appeared to be a prolonged need for catheteriza­
tion in both groups. The need for prolonged catheteriza­
tion can be explained by the laser-light effect itself. When 
a Nd:YAG laser beam is incident on prostatic tissue at
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power densities sufficient to coagulate the prostate, the 
gland shrinks to a minor extent due to the coagulation ef­
fect on protein and to the desiccation of the tissue. The 
prostate becomes rigid. This is followed by a period of 
cellular infiltration and swelling of the tissue. The patients 
will almost universally have a period of retention lasting
for an average of 5-20 days. Norris et al. [7] decided to 
leave the catheter indwelling for 5—7 days postoperatively, 
and only 17% of the patients required reinsertion of the 
catheter because of retention. In the present study we in­
serted a suprapubic catheter prior to treatment. Patients 
treated with the Ultraline fiber needed catheterization for 
an average of 18.9 days, whereas those treated with the 
Urolase fiber had their catheter removed at average on 
day 16.9. This may also explain the discomfort caused, 
expressed as irritative symptoms.
Therefore, it was suggested that one should move 
away from  purely coagulative techniques, which do not 
debulk the prostate to any measurable extent, toward 
a more vaporizing-oriented approach. This treatment 
modality causes tissue to convert into vapors of water and 
hydrocarbons, thus creating immediate cavitation. Al­
though we expected to create immediate cavitation using 
the Ultraline fiber, this did not occur. The results achieved 
with the Ultraline fiber are comparable with those found 
after treatment with the Urolase fiber. Evaporation of tis­
sue is favored by high-power density, and to obtain maxi­
mal power density it is important to keep the fiber close to 
(i.e., in contact with) the tissue. That we did not use the 
Ultraline fiber in constant contact with the tissue may ex­
plain why the extent of evaporation was less than ex­
pected. The main reason for not working in constant con­
tact was that we assumed a more rapid decay of the fibers 
as a result of contact lasing. Therefore, we think that the 
effect of the Ultraline fiber, at least in our hands, is a re­
sult o f coagulation and vaporization.
Narayan et al. [8] presented the results they obtained 
using the Ultraline fiber at a higher power setting. The 
main findings of their study were that in the short term 
transurethral evaporation of the prostate provided sympto­
matic relief and improvement in uroflow comparable to 
that of TURP [8], As pointed out above, we could not 
confirm this observation in using the Ultraline fiber. From 
our study we conclude that a significant reduction in symp­
tom scores and improvement in peak uroflow can be 
reached with this fiber. The present technique did not, as 
we expected, result in an earlier recovery of adequate 
spontaneous micturition and diminution of the symptoms. 
We think that the side-firing fibers, which are mainly used 
in the noncontact mode and at a relatively low power set­
ting, are currently incapable of creating sufficient cavita­
tion. The results presented by Narayan et al. suggest that 
besides being applied in contact, this fiber should be used 
at a higher power setting. The results of contact lasing are 
also very promising. These lasing devices seem to be ca­
pable of deobstructing prostates immediately [11].
As over 20 different devices are available at the mo­
ment, one would expect that these would differ in terms of 
response and outcome. The question as to the type of ap­
plicator that should be used is fundamental. In favor of a 
vaporizing technique is the observation that tissue is va­
porized and a cavity is created instantly. To our surprise, 
the results achieved with the fibers used in this study were 
similar. One might think that the general effect of laser 
light on tissue would be most important, not the device or 
technique used. However, Ansen and Watson [15] showed 
that pure coagulation treatment using the side-firing fibers
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appeared to show a higher success rate for the Urolase fiber 
as compared with the Myriadlase system. Another argu­
ment that fibers really differ in both their abilities and the 
outcome of treatment is provided by the results achieved 
with the contact lasing devices [11].
Besides the outcome of treatment and the morbidity 
caused, quality of life is another item to be addressed. An 
increasing number of (young) men with symptomatic 
BPH requiring treatment are concerned about their sexual 
functions. In the present study, retrograde ejaculation was 
found in 50% of the patients who were sexually active, 
whereas 14% mentioned diminished or absent erectile 
functions. Norris et al. [7] reported retrograde ejaculation 
in 3 of 37 sexually active men. According to Childs et al.
[14], absolutely no retrograde ejaculation was found after 
laser prostatectomy. Shanberg et al. [16] stated that ail pa­
tients who were sexually active prior to therapy main­
tained their potency and described no change in their erec­
tions. All but one patient maintained normal antegrade 
ejaculations as well. This discrepancy may have been 
caused by more extensive treatment near the bladder neck.
Although the results of laser treatment are encourag­
ing, the morbidity is considerably high. This is related to 
the device and technique used, among other factors. The 
optimal Nd:YAG power setting, time for energy delivery, 
and type of applicator used for laser treatment of the 
prostate have not yet been defined. The objective of laser 
treatment must be to find the technique that will maintain 
a clinically significant outcome while causing minimal 
posttreatment morbidity.
In conclusion, it is important to recognize that the term 
laser prostatectomy encompasses a wide variety of instru­
ments and techniques. The question regarding the appro­
priate technique and dosimetry has remained an enigma 
for all urologists. Each laser fiber has its own advantages 
and limitations, and no single formula exists for the ideal 
laser treatment. The present study shows no difference in 
the outcome.
References
1. Mebust WK, Holtgrewe HL, Cockett ATK, Peters PC, Writing 
Committee (1989) Transurethral prostatectomy: immediate 
and postoperative complications. A cooperative study o f 13 
participating institutions evaluating 3,885 patients. J Urol 141 :
243-247
2. Oesterling JE (1993) Stcnting the male urinary tract: a novel 
idea with much promise. J Urol 150:1648-1649
3. Schulman CC, Zlotta AR, Rasor JS, Hourriez L, Noel JC, 
Edwards SD (1993) Transurethral needle ablation (TUNA): 
safety, feasabiiity and tolerance o f  a new office procedure for 
treatment of benign prostatic hyperplasia. Eur Urol 2 4 :4 1 5 -  
423
4. Madersbacher S, Kratzik C, Szabo N, Susani M, Vingers L, 
Marberger M (1993) Tissue ablation in benign prostatic hyper­
plasia with high intensity focused ultrasound. Eur Urol 23 
[S uppl 1]: 3 9 -4 3
5. Devonee M, Berger N, Perrin B (1991) Transurethral mi­
crowave heating of the prostate or from hyperthermia to ther­
motherapy. J Endourol 5 :1 2 9 -1 3 6
6. Kabalin J (1993) Laser prostatectomy performed with a right 
angle firing Nd-YAG laser fiber at 40 Watts power setting. J 
Urol 1 5 0 :9 5 -9 9
7. Norris JP, Norris DM, Lee RD, Rubenstein MA (1993) Visual 
laser ablation o f the prostate: clinical experience in 108 pa­
tients. J Urol 150:1612-1614
8. Narayan P, Fournier G, Indudbara R, Leidich R, Shinohara K, 
Ingerman A (1994) Transurethral evaporation o f prostate 
(TUEP) with Nd:YAG laser using a contact free beam tech­
nique: results in 61 patients with benign prostatic hyperplasia. 
Urology 4 3 :8 1 3 -8 2 0
9. Costello AJ, Bowsher WG, Bolton DM , Braslis KG, Burt J 
(1992) Laser ablation of the prostate in patients with benign 
prostatic hypertrophy. Br J Urol 6 9 :6 0 3 -6 0 8
10. Takahashi S, Homma Y, Minowacla S, A so Y (1994) Trans­
urethral ultrasound-guided laser-induced prostatectomy (TULIP) 
for benign prostatic hyperplasia: clinical utility at one-year fol­
low up and imaging analysis. Urology 4 3 :8 0 2 —808
11. Watson G, Anson K> Janetschek G, Hominger W, Bartsch G 
(1994) An in-depth evaluation o f  contact laser vaporisation of 
the prostate. J Urol 1 5 1 :2 3 1 A
12. Rosette JJMCH de la, Froeling FMJA, Alivizatos G, Debruyne 
FMJ (1994) Laser ablation of the prostate: experience with an 
ultrasound guided technique and a procedure under direct v i­
sion. Eur Urol 2 5 :1 9 -2 4
13. Leach GE, Sirls L, Ganabathi K, Roskamp D, Drnochowski R 
(1994) Outpatient visual laser-assisted prostatectomy under lo­
cal anesthesia. Urology 43 :149-153
14. Childs S, Alabaster AL, Cowles RS, Dixon C, Kabalin JL, 
Lepor H, Stein E, Zabbo A (1993) Prospective randomized 
study comparing transurethral resection of the prostate to vi­
sual laser ablation of the prostate. J Urol 149:467 A
15. Anson KM, Watson G (1993) Lasers in the treatment o f benign 
prostatic hyperplasia. In: Puppo P (ed) Contemporary BPH 
management. Monduzzi editore, Bologna, pp 91-101
16. Shanberg AM* Lee IS, Tansey LA, Sawyer DE (1994) Exten­
sive neodym m m -YAG photoirradiation o f the prostate in men 
with obstructive prostatism. Urology 4 3 :4 6 7 -4 7 1
I
♦
